Teacher Retirement System of Texas Acquires 25,765 Shares of Hologic, Inc. $HOLX

Teacher Retirement System of Texas boosted its stake in shares of Hologic, Inc. (NASDAQ:HOLX) by 22.3% during the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 141,077 shares of the medical equipment provider’s stock after acquiring an additional 25,765 shares during the quarter. Teacher Retirement System of Texas owned about 0.06% of Hologic worth $9,521,000 as of its most recent SEC filing.

Several other hedge funds also recently added to or reduced their stakes in the company. Rakuten Investment Management Inc. bought a new position in shares of Hologic in the third quarter worth about $592,000. Universal Beteiligungs und Servicegesellschaft mbH grew its stake in Hologic by 12.6% in the 3rd quarter. Universal Beteiligungs und Servicegesellschaft mbH now owns 319,848 shares of the medical equipment provider’s stock worth $21,587,000 after acquiring an additional 35,667 shares in the last quarter. Inscription Capital LLC increased its position in shares of Hologic by 48.2% during the third quarter. Inscription Capital LLC now owns 7,703 shares of the medical equipment provider’s stock worth $520,000 after acquiring an additional 2,505 shares during the period. Root Financial Partners LLC bought a new stake in shares of Hologic during the third quarter valued at approximately $27,000. Finally, Allstate Corp purchased a new stake in shares of Hologic in the third quarter valued at approximately $531,000. 94.73% of the stock is currently owned by institutional investors.

Hologic Price Performance

NASDAQ HOLX opened at $75.05 on Monday. The company has a market cap of $16.75 billion, a price-to-earnings ratio of 30.26, a PEG ratio of 2.13 and a beta of 0.69. The company has a debt-to-equity ratio of 0.50, a current ratio of 3.75 and a quick ratio of 3.06. The stock’s fifty day moving average price is $74.80 and its 200 day moving average price is $70.60. Hologic, Inc. has a 1 year low of $51.90 and a 1 year high of $75.34.

Hologic (NASDAQ:HOLX) last issued its quarterly earnings results on Monday, November 3rd. The medical equipment provider reported $1.13 earnings per share for the quarter, topping the consensus estimate of $1.10 by $0.03. The company had revenue of $1.05 billion for the quarter, compared to the consensus estimate of $1.03 billion. Hologic had a net margin of 13.80% and a return on equity of 20.13%. Hologic’s quarterly revenue was up 6.2% on a year-over-year basis. During the same quarter in the prior year, the company earned $1.01 EPS. As a group, equities research analysts forecast that Hologic, Inc. will post 4.28 earnings per share for the current year.

Analyst Ratings Changes

HOLX has been the topic of several research reports. BNP Paribas Exane lowered Hologic from a “strong-buy” rating to a “hold” rating and set a $79.00 price target on the stock. in a research note on Friday, November 21st. BTIG Research reissued a “neutral” rating on shares of Hologic in a research report on Tuesday, October 21st. Argus lowered shares of Hologic from a “buy” rating to a “hold” rating in a report on Monday, January 12th. Mizuho cut shares of Hologic from an “outperform” rating to a “neutral” rating and upped their price target for the stock from $70.00 to $78.00 in a research report on Thursday, October 23rd. Finally, JPMorgan Chase & Co. reiterated a “neutral” rating and set a $78.00 price objective on shares of Hologic in a research note on Wednesday, October 22nd. Three equities research analysts have rated the stock with a Buy rating and thirteen have issued a Hold rating to the company. Based on data from MarketBeat, the company currently has an average rating of “Hold” and a consensus target price of $79.31.

Hologic Profile

Hologic, Inc (NASDAQ: HOLX) is a global medical technology company specializing in women’s health. Headquartered in Marlborough, Massachusetts, the company develops and manufactures diagnostic products, imaging systems and surgical solutions designed to detect, diagnose and treat diseases with a primary focus on breast and skeletal health, gynecological conditions and molecular diagnostics. Its product portfolio includes digital mammography systems, 3D mammography solutions, bone densitometry equipment and molecular assays for infectious disease and oncology applications.

Since its founding in 1985, Hologic has grown through both internal innovation and strategic acquisitions.